BioMarin
Trade BioMarin 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMRN
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.
BMRN Key Statistics
Stock Snapshot
With a market cap of 10.29B, BioMarin(BMRN) trades at $53.51. The stock has a price-to-earnings ratio of 40.56.
During the trading session on 2026-05-05, BioMarin(BMRN) shares reached a daily high of $57.44 and a low of $53.43. At a current price of $53.51, the stock is +0.1% higher than the low and still -6.8% under the high.
Trading activity shows a volume of 1.63M, compared to an average daily volume of 1.43M.
The stock's 52-week range extends from a low of $50.76 to a high of $66.28.
The stock's 52-week range extends from a low of $50.76 to a high of $66.28.
BMRN News
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on BioMarin (BMRN) to $119 from $120 and keeps an Overweight rating on the shares. Q1 reinfor...
Jason Gerberry, an analyst from Bank of America Securities, reiterated the Buy rating on BioMarin Pharmaceutical. The associated price target remains the same w...
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...
Analyst ratings
81%
of 27 ratingsMore BMRN News
Raises FY26 revenues view to $3.825B-$3.925 from $3.325B-$3.425B. Consensus is for FY26 EPS $4.64 and for revenue $3.83B. Updated guidance reflects post-close c...
Reports Q1 revenue $766M, consensus $751.68M. “With the acquisition of Amicus Therapeutics complete, the addition of GALAFOLD and POMBILITI + OPFOLDA to our com...
In early May 2026, BioMarin Pharmaceutical reported new VOXZOGO (vosoritide) data in children with achondroplasia, showing benefits beyond height, including imp...
BioMarin (BMRN) Pharmaceutical announced new research from studies of Voxzogo in children with achondroplasia demonstrating positive impact on important health...
Advertisement Recent performance snapshot BioMarin Pharmaceutical (BMRN) has drawn fresh attention after recent trading, with the share price at US$54.06 and...
BioMarin Pharmaceutical (NasdaqGS:BMRN) has completed its acquisition of Amicus Therapeutics. The deal adds two approved lysosomal storage disease treatments t...
BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, previously listed as NasdaqGM:FOLD. Following the transaction, Amicus has been de...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.